JP2008543795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543795A5 JP2008543795A5 JP2008516161A JP2008516161A JP2008543795A5 JP 2008543795 A5 JP2008543795 A5 JP 2008543795A5 JP 2008516161 A JP2008516161 A JP 2008516161A JP 2008516161 A JP2008516161 A JP 2008516161A JP 2008543795 A5 JP2008543795 A5 JP 2008543795A5
- Authority
- JP
- Japan
- Prior art keywords
- azabicyclo
- octane
- chlorobenzyl
- endo
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 Hydroxy, phenoxy Chemical group 0.000 claims description 43
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 102000004500 CCR1 Receptors Human genes 0.000 claims 3
- 108010017319 CCR1 Receptors Proteins 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010019315 Heart transplant rejection Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010023439 Kidney transplant rejection Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000009961 allergic asthma Diseases 0.000 claims 3
- 230000001668 ameliorated effect Effects 0.000 claims 3
- 230000008485 antagonism Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 claims 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 claims 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 claims 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 229940126560 MAPK inhibitor Drugs 0.000 claims 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052801 chlorine Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical group OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960000581 salicylamide Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)([C@]1C[C@](CC2)*(*)C2C1)C(CC*(*)C[C@@](C1)CIC[C@@]1N)=O Chemical compound CC(C)([C@]1C[C@](CC2)*(*)C2C1)C(CC*(*)C[C@@](C1)CIC[C@@]1N)=O 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200501431A ES2277745B1 (es) | 2005-06-14 | 2005-06-14 | Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1. |
| PCT/EP2006/005129 WO2006133802A1 (en) | 2005-06-14 | 2006-05-30 | N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as ccr1 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008543795A JP2008543795A (ja) | 2008-12-04 |
| JP2008543795A5 true JP2008543795A5 (enExample) | 2009-06-04 |
Family
ID=35740673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008516161A Withdrawn JP2008543795A (ja) | 2005-06-14 | 2006-05-30 | Ｃｃｒ１アンタゴニストとしての８−アザビシクロ［３．２．１］オクト−３−イルのｎ−アミド誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090130090A1 (enExample) |
| EP (1) | EP1891064B1 (enExample) |
| JP (1) | JP2008543795A (enExample) |
| CN (1) | CN101228158A (enExample) |
| AR (1) | AR057651A1 (enExample) |
| AT (1) | ATE441647T1 (enExample) |
| DE (1) | DE602006008937D1 (enExample) |
| ES (2) | ES2277745B1 (enExample) |
| PE (1) | PE20070017A1 (enExample) |
| TW (1) | TW200716626A (enExample) |
| UY (1) | UY29572A1 (enExample) |
| WO (1) | WO2006133802A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197914A1 (en) * | 2006-03-07 | 2009-08-06 | Peter Cage | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them |
| ES2400875T3 (es) | 2008-04-11 | 2013-04-15 | Janssen Pharmaceutica N.V. | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno A4 hidrolasa |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| JP5746685B2 (ja) | 2009-05-14 | 2015-07-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | ロイコトリエンａ４加水分解酵素のモジュレーターとしての縮合二環式ヘテロアリール部分を２つ有する化合物 |
| WO2011087812A1 (en) * | 2009-12-21 | 2011-07-21 | Vanderbilt University | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| EP2875023B1 (en) * | 2012-07-19 | 2017-04-05 | Janssen Pharmaceutica NV | Octahydro-cyclopentapyrrolyl antagonists of ccr2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998004554A1 (en) * | 1996-07-29 | 1998-02-05 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| SE0200919D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Chemical compounds |
| BR0312699A (pt) * | 2002-07-18 | 2005-04-26 | Pfizer Prod Inc | Derivados de piperidina bicìclica como antagonistas de receptor de quimiocina ccr1 |
| SE0301369D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
-
2005
- 2005-06-14 ES ES200501431A patent/ES2277745B1/es not_active Expired - Fee Related
-
2006
- 2006-05-30 JP JP2008516161A patent/JP2008543795A/ja not_active Withdrawn
- 2006-05-30 AT AT06753965T patent/ATE441647T1/de not_active IP Right Cessation
- 2006-05-30 CN CNA2006800266367A patent/CN101228158A/zh active Pending
- 2006-05-30 UY UY29572A patent/UY29572A1/es unknown
- 2006-05-30 US US11/921,961 patent/US20090130090A1/en not_active Abandoned
- 2006-05-30 DE DE602006008937T patent/DE602006008937D1/de active Active
- 2006-05-30 EP EP06753965A patent/EP1891064B1/en active Active
- 2006-05-30 WO PCT/EP2006/005129 patent/WO2006133802A1/en not_active Ceased
- 2006-05-30 ES ES06753965T patent/ES2332819T3/es active Active
- 2006-06-12 PE PE2006000656A patent/PE20070017A1/es not_active Application Discontinuation
- 2006-06-12 AR ARP060102442A patent/AR057651A1/es not_active Application Discontinuation
- 2006-06-13 TW TW095121003A patent/TW200716626A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534421A5 (enExample) | ||
| US20240067630A1 (en) | Aryl ether-substituted heterocyclic compounds as glp1r agonists | |
| US10005731B2 (en) | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
| US9630945B2 (en) | Autotaxin inhibitors | |
| JP4070957B2 (ja) | フェニルおよびピリジニル誘導体 | |
| ES2738826T3 (es) | Compuestos de piridilo sustituidos con alquilamida útiles como moduladores de respuestas de IL-12, IL-23 y/o IFNalfa | |
| JP4742026B2 (ja) | ロフルミラストの新規の製造方法 | |
| HRP20120579T1 (hr) | Antagonisti receptora il-8 | |
| US7196100B2 (en) | Opioid receptor antagonists | |
| JP2021504443A (ja) | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 | |
| NZ582056A (en) | Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation | |
| US9409895B2 (en) | Autotaxin inhibitors | |
| TW201041870A (en) | New compounds | |
| JP2008543795A5 (enExample) | ||
| TW200307545A (en) | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases | |
| TW200305417A (en) | Chemical compounds | |
| ZA200604395B (en) | Novel M3 Muscarinic Acetylcholine receptor antagonists | |
| UA77969C2 (en) | Piperidine derivatives and their use for modulating ccr5 receptor activity, process for their manufacture, pharmaceutical composition and intermediate compound | |
| JP2011500543A (ja) | ２−および３−位において置換されている５，６−ジアリールピリジン、これらの調製およびこれらの治療上の使用 | |
| TW200407140A (en) | Chemical compounds | |
| JP2018536709A5 (ja) | 脳神経の耳麻酔による疾患の治療用組成物 | |
| SK4642003A3 (en) | Bridged piperazine derivatives | |
| ES2332819T3 (es) | Derivados n-amida de 8-azabiciclo(3.2.1.)oct-3-ilo como antagonistas de ccr1. | |
| JP2009519988A5 (enExample) | ||
| RU2015115677A (ru) | Производные 6-аминоиндола в качестве антагонистов канала с транзиторным рецепторным потенциалом (trp) |